AZACTAM

aztreonam

IN CYSTIC FIBROSIS

A logical choice for pseudomonal infections



ABBREVIATED PRESCRIBING INFORMATION AZACTAM

Presentation Vials containing 500mg, 1g, 2g aztreonam. Infusion bottle containing 2g aztreonam. All with L-arginine. Indications for the treatment of the following infections caused by

susceptible aerobic Gram-negative micro-organisms: Jirinary tractics used by susceptible aerobic Gram-negative micro-organisms: Jirinary tractic (inciding present in the constitution of the constitution of

Dosage and administration Adults: Ig-8g daily in divided doses depending on site and severity of infection. The usual dose is 3-4g daily. In serious infections a dose of 6-8g daily is recommended. In cystic fibrosis 2g 6-8 hourly IV. Gonorrinea/cystitis 1g im. single dose. Children: patients older than 1 week 30mg/kg/dose every 6-8 hours. For severe infections in patients 2 years of age or older, 50mg/kg/dose every 6 or 8 hours is recommended. Total daily dose should not exceed 8g. Dosage information not available for newborns less than 1 week old. Azactam can be given intravenously or intramuscularly. Intravenous injection or Infusion is recommended for doses greater than 1g. Adjust dosage in renal impairment. (See Data Sheet.) Contra-indications Patients with a known hypersensitivity to Azactam Pregnancy.

Precautions Initial concurrent therapy with other antibiotics is recommended for infections which may be due to non-susceptible organisms. [See Data Sheet.] Lactating mothers should refrain from breast feeding. Therapy with Azactam may result in superinfections which may require additional therapy, impaired renal/hepatic function. Caution should be exercised in patients with beta-lactam pypersensitivity. Protmombin times should be monitored in patients with concomitant anticosignal therapy.

Side effects Aztreonam is generally well tolerated. Side-effects include rash, local reactions at the injection site, diarrhoea, nausea, vomiting.

(See Data Sheet.)

Product Licence No./Cost Azactam injection 500mg vial PL0034/ 0250 £4 48, Ig vial PL0034/0251 £8.95, 29 vial PL0034/0252 £1790, 2g mission bottle PL0034/0255 £1790. Product Licence Holder E R Squibb and Sons Ltd, Squibb House, Hounslow Middlesex TWS 3.1 A

Date of preparation May 1989.



E.R. Squibb & Sons Limited, Squibb House, 141-149 Staines Road, Hounslow, Middlesex TW3 3JA.



For the effective nutritional care of infants with malabsorption problems, the answer may be elemental.

Pepti-Junior is a balanced elemental feed, which is easily digested and well absorbed. It has been specially developed for infants and young children with digestive or malabsorption problems and or severe food intolerances.

Pepti-Junior is well tolerated, with a highly palatable taste.

The formulation comprises hydrolysed whey protein, glucose syrup, MCT oil, maize oil, minerals and vitamins.

Osmolality is low at 210 mosmol/kg H₂0.

Pepti-Junior is ACBS prescribable, and the latest addition to the extensive Cow & Gate range of Specialised Formula Foods.



The balanced elemental formula for infant malabsorption

References 1. Taylor CJ, Jenkins P, Manning D Clinical Nutrition, 1988; 7: 183-190. 2. Keohane PP, Grimble GK, Brown B et al. Gut, 1985; 26: 907-913. 3. Silk DBA et al. JPEN, 1980; 4: 548-553. 4. Silk DBA et al Gut 1979; 20: 291-299. Breast milk is the best milk for babies. PEPTI-JUNIOR has been prepared for infants with impaired gastrointestinal function and/or severe food intolerances. PEPTI-JUNIOR should only be used under strict medical supervision. For further information contact Cow & Gate, Medical Department, Trowbridge, Wiltshire BA14 8YX. (0225 768381).

THE PANCREATIN MICROSPHERE PREPARATION WITH THE HIGHEST GUARANTEED POTENCY.




66 The size of microspheres of pancreatin should be such that they empty at least as fast as the food they are intended to digest. ?? Gelatin capsule containing enteric coated acid resistant microspheres of Lipase, Amylase and Protease.

> Capsule dissolves in gastric fluids; microspheres remain intact and disperse throughout chyme.

> Enteric coating of microspheres dissolves in duodenum at pH of 5, releasing enzymes for digestion of food.

6 Recent reports on both Cystic Fibrosis and Adult Chronic Pancreatitis have demonstrated that duodenal postprandial pH... is frequently less than pH 5.5...)²




FEWER CAPSULES NEEDED

At equal doses of lipase Nutrizym GR has been shown to result in equivalent lipid digestion and absorption with less than half as many capsules as required by preparation B³ (see bar chart for enzyme concentrations).

GREATER CONVENIENCE ENHANCES COMPLIANCE

It has been shown that Cystic Fibrosis patients prefer the convenience of effective pancreatin regimens in the form of microsphere capsules, compared to enteric coated tablets. 4





Its strong point is its strength.

REFERENCES 1) Meyer JH et al, Gastroenterology, 1988, Vol. 94, No. 6, 1315-25. 3) Dodge JA & Matthews EE (Data on file).

2) Littlewood JM, Kelleher J, Walters MP & Johnson AW, J Paediatr. 4) Stead RJ et al, Thorax, 1987, Vol. 42, 533-537. Gastroenterol. Nutr., 1988, Vol. 7, Suppl. 1, 522-529.

Further information is available on request from E Merck Ltd, FREEPOST, Winchester Road, Four Marks, Alton, Hants GU34 5HG Telephone: (0420) 64011.

NUTRIZYM GR - Prescribing Information
Each capsule contains enteric coated pellets of Pancreatin BP 300 mg with not less
than the following activities
Lipase 10,000 BPU, Protease 650 BPU, Amylase 10,000 BPU
Use: Fibrocystic disease of the pancreas, chronic pancreatitis, steatorrhoea and other

Use: Horocystic disease of the pancreas, chronic pancreatus, steatormore and outer pancreatic deficiency states.

Dosage and Administration: Usually 1 - 2 capsules with meals.

Capsules should be swallowed whole with water or contents sprinkled on food. Pellets should not be chewed.

Contra-indications: Known hypersensitivity to porcine pancreatin.

Precautions: Hyperuricaemia and hyperuricosuria have been reported to occur in

cystic fibrosis patients; pancreatin extracts contain a very small amount of purine which might, in high dose, contribute to this condition.

Use in Pregnancy: Safety in pregnancy has not been established.

Side effects: Very rarely hypersensitivity reactions. High doses may cause buccal and perianal irritation, in rare cases amounting to inflammation.

Pharmaceutical Precautions

Store below 25°C in tightly closed containers.


Package quantities

Containers of 100 capsules (OP) PL 0493/0121; NHS Price: £12.52 at February 1990

MERCK

PROGRESS

In The Management Of Cystic Fibrosis





RIGHT ON TARGET - RIGHT FROM THE START

Prescribing Information — Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. Indication: Pancreatic exocrine insufficiency. Dosage and administration: Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosurla and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. Product Licence Number: 5727/0001. Name and address of Licence Holder: Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

The loudest noise in your S.C.B.U. should be the sound of babies sleeping

But how often have you walked into the Special Care Baby Unit only to be greeted by a wall of noise?

We all know babies nursed in incubators need rest — indeed most of them should still be in the calm of the womb.

But invariably they require attention from Doctors, Nurses and parents, often on a frequent basis.

So how do you access the baby without causing it major physical and psychological stresses?

That's where the new C100 Quiet Touch Isolette incubator comes in.


It's the ultimate low noise environment for the neonate.

It has large oval port holes that can be opened and closed so quietly that your baby won't even notice.

It includes a smooth, continuously variable mattress tilt enabling your baby to remain at peace whilst travelling through a full 9 degrees in either direction.

And how many times have you had to search the SCBU for a suitable chair for parents to sit on, enabling that all important early contact with the baby?

Well, that's no longer a problem.



With the touch of a foot pedal, the new Variable Height Adjustment (VHA) mechanism on the C100 Quiet Touch allows continuous control of the baby's level from a towering 43 inches to a low 34.5 inches — just right for a comfortable armchair.

Once you have a C100 Quiet Touch Isolette you'll never want anything else, and when your babies wake up we think they'll agree.




SAW Vickers

Ruxley Corner, Sidcup, Kent, DA14 5BL. Tel 081-309 0433 Fax 081-309 0919

32 Kerse Road, Stirling, FK7 7TA. Tel 0786 51602 Fax 0786 51603

4 Balmoral Business Park, Boucher Cresent, Belfast. Tel 0232 669266



NORDITROPIN somatropin (epr) ABBREVIATED PRESCRIBING INFORMATION ▼ Presentation: Vial of sterile powder containing somatropin (epr) 12 iu supplied with 3 ml vial of sterile diluent containing m-cresol 2.5 mg/ml. Uses: Treatment of short stature prior to epiphyseal fusion due to inadequate secretion of endogenous growth hormone. Dosage and Administration: Dosage is individual, generally 2-3 iu/m² (0.07-0.1 iu/kg) s.c. 6-7 times per week is recommended. The injection site should be varied to prevent lipoatrophy. Contra Indications: Evidence of active tumour or recurrent tumour growth. Precautions: Patients should be regularly assessed by a specialist in child growth. Use with caution in patients with diabetes or a family history of diabetes; regular testing for glycosuria should be carried out in all patients. Hypothyroidism or concomitant glucocorticoid therapy may interfere with the response to human growth hormone, patients should have periodic thyroid function tests. Patients with a history of intracranial lesion should be monitored frequently for any recurrence of the lesion.

Pregnancy and Lactation: In the event of pregnancy occurring during

Pregnancy and Lactation: In the event of pregnancy occurring during Norditropin treatment, therapy should be discontinued. The possibility that Norditropin is secreted in breast milk cannot be discounted. Side Effects: Discomfort at the injection site has been reported occasionally.

Antibody formation occurs rarely but is generally not of clinical significance. **Overdosage**: Acute overdosage may lead initially to hypoglycaemia followed by hyperglycaemia. Long-term overdosage may result in a syndrome consistent with human growth hormone excess. **Pharmaceutical Precautions**: Store at 2-8°C and protect from sunlight. After reconstitution the solution may be stored for up to 7 days at 2-8°C protected from sunlight, but should not be frozen. **Legal Category:** POM. **Package Quantities**: Package containing one vial Norditropin 12 iu and one vial 3 ml sterile diluent. **Product Licence Number:** Norditropin 12 iu: 3132/0046 Diluent: 3132/0047.

Product Licence Number: Norditropin 12 iu: 3132/0046 Diluent: 3132/0047.
Price: E91.50. Name & Address of PL Holder: Nordisk UK Ltd, Nordisk House, Garland Court, Carland Road, East Crinstead, West Sussex, RH19 1DN.

Further information is available from: Nordisk UK, Nordisk House, Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. Tel: East Grinstead (0342) 410373 *Registered Trade Mark The Department of Pediatrics at the Texas Tech University Health Sciences Center, Lubbock, Texas is recruiting a chairperson. Major responsibilities would include departmental administration, curriculum development, residency program, patient care, and research development. The position also includes the supervision of the Pediatric Departments at the Texas Tech University, three regional campuses in El Paso, Amarillo and Odessa through the Associate Chairmen.

Interested applicants should submit their curriculum vitae and arrange for letters of reference to be sent to:

Robert P. Carter, M.D.

Associate Dean
Chairman Of The Search Committee For
The Department of Pediatrics
Texas Tech Regional Academic
Health Center
800 W. Fourth Street
Odessa, Texas 79763



INSTITUTE OF PSYCHIATRY AND INSTITUTE OF CHILD HEALTH

UNIVERSITY OF LONDON

Diploma in Child and Adolescent Psychiatry

An International Course

A one year course leading to a Diploma in Child and Adolescent Psychiatry will start in January 1991. This annual course is run jointly in London by the Institute of Psychiatry and the Institute of Child Health. It covers diagnosis and treatment of children and adolescents with psychiatric disorders including those with physical illness and chronic handicap; assessment of community needs in relation to Child Mental Health, with a view to planning or implementing psychiatric services in the participant's own country; teaching and training medical and paramedical workers. The course will be particularly suitable for paediatricians, psychiatrists and psychologists intending to set up or work in child mental health services in developing countries. Good English is essential. A scholarship may be available for a suitably qualified candidate.

Course Teachers will include: Dr A Bentovim, Dr D Black, Dr C Dare, Dr A Gath, Prof P Graham, Dr G Hodges, Dr R Howarth, Dr P Howlin, Dr R Lansdown, Dr B Lask, Dr A Nikapota, Dr N Richman, Prof M Rutter, Dr C Sheldrick, Dr D Skuse, Dr D Steinberg, Dr J Strang, Dr E Taylor, Dr S Wolkind, Prof W Yule.

Further details available from: Dr A Gath, Institute of Psychiatry, Department of Child and Adolescent Psychiatry, 16 De Crespigny Park, Denmark Hill, London SE5 8AF. Applications should be returned by 1 June 1990.

European Journal of

Pediatrics

Incorporating
Acta Paediatrica Belgica
and
Helvetica Paediatrica Acta

Volume 149 No. 4 1990

The pioneers of pediatric medicine 223

Review

Immunological features of diffuse connective tissue diseases
G. R. Burgio, A. Martini 224

Endocrinology

Daily profiles of salivary cortisol in hydrocortisone treated children with congenital adrenal hyperplasia R. Hampl, L. Foretová, J. Šulcová, L. Stárka 232

Panhypopituitarism without diabetes insipidus: magnetic resonance imaging of pituitary stalk transection C. Christophe, G. Van Vliet, G. Dooms, M. Lemort, N. Perlmutter, C. Segebarth, D. Balériaux 235

Prenatal treatment of congenital adrenal hyperplasia: report of a new case

G. A. Loeuille, M. David, M. G. Forest 237

Gastroenterology/Hepatology

A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis. A controlled study

H. Vyas, D. J. Matthew, P. J. Milla 241

Milk-sensitive eosinophilic gastroenteritis in a 10-day-old boy Y. Vandenplas, M. Quenon, F. Renders, I. Dab, H. Loeb 244

Growth/Development

Linear growth in patients with Turner syndrome: influence of spontaneous puberty and parental height G. Massa, M. Vanderschueren-

G. Massa, M. Vanderschueren-Lodeweyckx, P. Malvaux **246**

Hematology/Oncology

Major malformations in a case of infantile myofibromatosis
M. Michel, J. Ninane, D. Claus,
S. Gosseye, F.X. Wese, D. Moulin

251

Imaging techniques

Colour Doppler imaging – a new method to differentiate torsion of the spermatic cord and epididymo-orchitis K.-H. Deeg, F. Wild 253

Infectious diseases

Evaluation of two ELISA tests for the rapid detection of group A Streptococci

P. Egger, C. A. Siegrist, G. Strautmann, D. Belli, R. Auckenthaler **256**

Escherichia coli 0157: H7 infections associated with perforated appendicitis and chronic diarrhoea N. Cimolai, J. D. Anderson, N. M. F. Bhanji, L. Chen, G. K. Blair 259

Congenital cytomegalovirus infection in a twin pregnancy: a case report J. J. Duvekot, B. A. M. Theewes, J. M. Wesdorp, F. J. M. E. Roumen, P. X. J. M. Bouckaert 261

Medical genetics

Deletion screening and prenatal diagnosis of Duchenne muscular dystrophy using cDNA probes Cf23a and Cf56a

F. H. Herrmann, K. Wulff, M. Schütz, M. Wehnert **263**

Proximal phocomelia and radial ray aplasia in fetal valproic syndrome

A. Verloes, A. Frikiche, C. Gremillet, T. Paquay, T. Decortis, J. Rigo, J. Senterre **266** Metabolic diseases

The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients

P. J. Willems, W. J. M. Gerver, R. Berger, J. Fernandes 268

A case of carbamylphosphate synthetase-I deficiency associated with secondary carnitine deficiency – L-carnitine treatment of CPS-I deficiency

T. Mori, A. Tsuchiyama, K. Nagai, M. Nagao, K. Oyanagi, S. Tsugawa

Neonatology

Incidence and duration of total occlusion of the radial artery in newborn infants after catheter removal W. W. M. Hack, A. Vos, J. van der Lei, A. Okken 275

Dangerous effects of tinprotoporphyrin plus photoirradiation on neonatal rats

H. Keino, H. Nagae, S. Mimura, K. Watanabe, S. Kashiwamata **278**

Effects of bovine surfactant in premature lambs after intra-tracheal application

L. Gortner, F. Pohlandt, B. Disse, E. Weller **280**

Prospective study on the prevalence of sudden infant death and possible risk factors in Brussels: preliminary results (1987–1988)

A. Kahn, A. Wachholder, M. Winkler, E. Rebuffat **284**

Nephrology/Urology

Renal blood flow and flow velocity in children and adolescents: Duplex Doppler evaluation

D. Grunett, M. Schöning, W. Posendebl

D. Grunert, M. Schöning, W. Rosendahl **287**

Neuropediatrics

The prognosis of convulsions during childhood shigellosis

A. Zvulunov, M. Lerman, S. Ashkenazi, R. Weitz, M. Nitzan, G. Dinari **293**

Indexed in Current Contents



Subscription information

Volume 149 (12 issues) will appear in 1990. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 868.00 (single issue price approx. \$ 87.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to: Springer-Verlag New York Inc. Service Center Secaucus 44 Hartz Way Secaucus, NJ 07094, USA Tel. (201) 348-4033 Telex 023125994 FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1532.00 plus carriage charges; Federal Republic of Germany: DM 20.54 incl. value added tax; all other countries: DM 39.00 except for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 103.80, India DM 75.00, Australia/New Zealand DM 119.40. Airmail delivery to all other countries is available upon request. Volume price: DM 1532.00, single issue price: DM 153.20 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag Heidelberger Platz 3, D-1000 Berlin 33 Tel. (0)30/8207-0, Telex 183319 FAX (0)30/8214091

MONATS KINDER SCHRIFT HEILKUNDE

138. Band Heft 1 Januar 1990 Organ der Deutschen Gesellschaft für Kinderheilkunde

Thema des Monats

Risiken der Hormonanwendung bei nahrungsmittelliefernden Tieren

Editorial 1

H. Karg Zur aktuellen Situation und Risikobewertung der Anwendung von Hormonpräparaten bei nahrungsmittelliefernden Tieren 2

Pädiatrie aktuell

Dexamethason bei der bronchopulmonalen Dysplasie (BPD) Frühgeborener

Prophylaktische Unterbindung des offenen Ductus arteriosus bei Frühgeborenen unter 1000 g Geburtsgewicht

Exanthema subitum ohne Fieber 6

Was hat das Kind?

Trainingsprogramm für die Weiterbildung zum Kinderarzt 7

Klinik und Forschung

L. Gortner, F. Pohlandt, P. Bartmann, B. Disse Die Behandlung des Atemnotsyndroms (RDS) sehr kleiner Frühgeborener mit bovinem Surfactant 8

A. Huber, G. Hafner Wertigkeit des Elastasealpha₁-Proteinaseinhibitor-Komplexes bei pädiatrischonkologischen Patienten mit Fieber 13

H. G. Dörr, W. G. Sippell, F. Bidlingmaier, V. Berges, D. Knorr Erfahrungen mit einem gezielten Screening zur Früherkennung des kongenitalen adrenogenitalen Syndroms (AGS) mit 21-Hydroxylase-Defekt 17

D. Körholz, U. Wahn, H. Jürgens, V. Wahn Allergische Reaktionen unter der Behandlung mit L-Asparaginase. Bedeutung spezifischer IgE-Antikörner 23

P. Hadjilaskari, S. Brühmüller, R. Fengler, R. Hartmann, J. Waldschmidt, G. Henze Langzeiterfahrungen mit zentralvenösen Kathetern in der pädiatrischen Onkologie 26

Der interessante Fall

M. Krause, P. Meinecke, M. Krins, W. Grote Das Hypertelorismus-Hypospadie-(BBB)-Syndrom. Zwei weitere Familienbeobachtungen 31

M. Holder, F. Majewski, H. G. Lenard Hypoplasie der Nägel und Endphalangen als Folge pränataler Barbiturat-Exposition 34

W. Jost, N. Graf, G. Pindur, F. C. Sitzmann Intraspinale, extradurale Blutung bei einem 7jährigen Jungen mit Hämophilie B 36

B. Wilken, F. Aksu, C. v. d. Lühe, E. Reusche, H. Arnold Intraspinales Astrozytom bei einem 3jährigen Mädchen 38

Was hat das Kind?


Auflösung und Kommentar des Trainingsprogramms für die Weiterbildung zum Kinderarzt 22

Neue Bücher 41
Tagesgeschichte,
Personalia 43
Tagungskalender 44



Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong

Annual subscription: DM 298,- plus postage



Abbreviated Prescribing Information PenMix® 30/70 100iu/ml (Biphasic Isophane Insulin Injection 30/70. Human Insulin (pyr). Indications: The treatment of insulin-requiring diabetics. Dosage and Administration: The dosage is determined by the Physician according to the needs of the patient. Given by subcutaneous injection and intended for use in the NovoPen and NovoPen II injection devices only. (See instructions for use of devices.) Resuspend before use by agitating up and down. Contra-indications: Hypoglycaemia. Precautions: Injections of PenMix 30/70 should be followed by a meal within 30 minutes of administration. A dosage reduction may be required on transfer from bovine or mixed species insulin. Reduction of early warning symptoms for hypoglycaemia reported by a few patients on transfer from animal source to human insulin. Beta blockers, MAOTs and alcohol may enhance hypoglycaemic effect of insulin. Corticostoids, thyroid hormones, oral contraceptives may increase insulin requirements. Use in Pregnancy: Insulin

requirements usually fall during first trimester and increase during second and third trimester. Side-effects: Lipodystrophy insulin resistance and hypersensitivity are rarely reported with human insulin. Product Licence Number and Basic NHS Price: PL 4668/0020, 5×1.5ml cartridges £8.10. Product Licence Holder: Novo Industri A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark. Sole Distributor: : Farillon Limited, Ashton Road, Harold Hill, Romford, Essex RM3 8UE. Further Information is available on request from: Novo Nordisk Pharmaceuticals Ltd, Ringway House, Bell Road, Daneshill East, Basingstoke,

Hampshire, RG24 0QN. Tel: 0256 55055.

*Registered Trade Mark of Novo Nordisk A/S

February 1990

Leading the way in diabetic care